XMD17-109
目录号: PL04494 纯度: ≥99%
CAS No. :1435488-37-1
商品编号 规格 价格 会员价 是否有货 数量
PL04494-5mg 5mg ¥1607.00 请登录
PL04494-10mg 10mg ¥2893.00 请登录
PL04494-50mg 50mg ¥9322.00 请登录
PL04494-100mg 100mg ¥12858.00 请登录
PL04494-200mg 200mg 询价 询价
PL04494-500mg 500mg 询价 询价
PL04494-10mM*1mLinDMSO 10mM*1mLinDMSO ¥2258.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
XMD17-109
中文别名
11-环戊基-2-[[2-乙氧基-4-[[4-(4-甲基-1-哌嗪基)-1-哌啶基]羰基]苯基]氨基]-5,11-二氢-5-甲基-6H-嘧啶并[4,5-B][1,4]苯并二氮杂卓-6-酮;XMD17-109 抑制剂
英文名称
XMD17-109
英文别名
XMD17-109;11-cyclopentyl-2-[[2-ethoxy-4-[[4-(4-methyl-1-piperazinyl)-1-piperidinyl]carbonyl]phenyl]amino]-5,11-dihydro-5-methyl-6H-Pyrimido[4,5-b][1,4]benzodiazepin-6-one;11-cyclopentyl-2-[2-ethoxy-4-[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]anilino]-5-methylpyrimido[4,5-b][1,4]benzodiazepin-6-one;ERK5-IN-1;XMD17 109;11-Cyclopentyl-2-((2-ethoxy-4-(4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl)-phenyl)amino)-5-methyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one
Cas No.
1435488-37-1
分子式
C36H46N8O3
分子量
638.80
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
XMD17-109 是一种特异性的 ERK-5 抑制剂,IC50 值为 162 nM。
生物活性
XMD17-109 is a novel, specific ERK-5 inhibitor, with an IC 50 of 162 nM.
性状
Solid
IC50 & Target[1][2]
ERK5 162 nM (IC50) LRRK2[G2019S] 339 nM (I
体外研究(In Vitro)
XMD17-109 (Compound 26) inhibits ERK5 biochemically with an IC50 of 0.162 ± 0.006 μM, and blocks pidermal growth factor induced ERK5 autophosphorylation with an EC50 of 0.09 ± 0.03 μM in cells. XMD17-109 also inhibits LRRK2[G2019S] with an IC50 of 339 nM. XMD17-109 demonstrats low nanomolar cellular activity judged by the significant dose-dependent reduction of mobility shifted phosphorylated ERK5 bands from sorbitol stimulated cells. XMD17-109 completely inhibits the ERK5-mediated AP1 transcriptional activity at 30 μM and has an EC50 of 4.2 μM. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Deng X, et al. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. Eur J Med Chem. 2013;70:758-67.
[2]. Elkins, Jonathan M., et al. X-ray Crystal Structure of ERK5 (MAPK7) in Complex with a Specific Inhibitor. Journal of Medicinal Chemistry (2013), 56(11), 4413-4421.
溶解度数据
In Vitro: DMSO : ≥ 100 mg/mL (156.54 mM)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2